Questions we hear most

Never. Member genetic results go directly to the member and their treating clinician. Employers, plan sponsors, insurers, TPAs, and disability management organizations do not have access to individual member results under any circumstances. The only aggregate data shared with plan administrators are utilization rates and general outcomes trends which contains no individual identifying information. This separation is a foundational principle of how Inagene operates.

All member genetic data is stored in Canadian data centers and processed in Inagene's own Canadian laboratory. Data never leaves Canadian jurisdiction. Inagene operates in compliance with applicable Canadian federal and provincial privacy legislation, and all data handling is governed by Inagene's privacy framework. No third party has access to member genetic data without explicit member consent.

No. Canadian law prohibits insurers and employers from using genetic test results to make decisions about coverage, premiums, or employment. Members can complete Inagene's test with full confidence that their results will not affect their insurance status or employment in any way. Inagene recommends that organization use our promotional materials to communicate this early and clearly to members as part of the program launch.

Inagene is designed to complement existing programs rather than replace or disrupt them. For benefit plans, Inagene can be added as a managed benefit with member communications and utilization support handled by Inagene's account management team, which will minimize administrative lift for the plan sponsor or TPA. For disability management programs, Inagene integrates at the case manager level as part of their workflow: when a case manager identifies medication response as a likely barrier to recovery, a simple referral initiates the process. Results go directly to the member and their treating clinician, with no additional work for the case management team.

Results vary by population and program design, but the clinical evidence and early program data point to meaningful impact across three areas: reduced medication trial-and-error (and the associated drug spend waste), shorter disability claim duration for cases where medication ineffectiveness is a contributing factor, and improved member outcomes as prescribers make more informed decisions. Inagene provides anonymized, plan-level data reporting on an ongoing basis so organizations can track program impact over time.

Implementation timeline varies depending on the organization type and scope of deployment. Inagene's account management team works with each partner organization to design the program, develop member communications, train relevant staff, and establish check-in and reporting cadences before launch. Most implementations can be completed within a few weeks of agreement. Contact us to discuss a timeline specific to your organization.

Ongoing account management is built into every Inagene program. After launch, Inagene provides continued member engagement support and communications, utilization tracking, program performance reporting, and access to updated resources as the medication database grows. Organizations are not left to drive adoption on their own.

Voluntary PGx coverage, where members claim reimbursement for a test they would seek out themselves, typically generates very low utilization. The members who would benefit most from pharmacogenetic guidance rarely seek it out proactively, which means the clinical and financial value of the coverage goes largely unrealized. Inagene's managed program is designed to actively reach the right members at the right time, with account management and member communications support that drives meaningful utilization rather than passive availability.

Inagene supports benefits consultants with the materials and knowledge needed to have confident conversations with plan sponsor clients, including plan-level modeling, case study data, and presentation support. The core conversation is straightforward: rising drug costs and disability claims have a root cause that existing programs don't address, and Inagene is the upstream intervention that changes that equation. Contact us to discuss how we can support your next client conversation.

When a case manager encounters a claim that is stalling despite appropriate care and a solid return-to-work plan in place, they may identify medication response as a likely barrier to recovery. In this case they can initiate a referral to Inagene. The member receives a test kit, completes the swab at home, and results are delivered to the member and their treating clinician within 7–10 business days. The case manager is notified that the process is underway and can follow up with the treating clinician to ensure results are being actioned. The entire process is designed to add a clinically actionable step without adding administrative burden to the case management team.